Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PhaseI/II, Multicenter, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the Menin Inhibitor BN104 in the Treatment of Patients With Relapsed/Refractory Acute Leukemia

NCT06052813 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier (I.R.I.S.) as lead sponsor.

NCT NCT06052813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PhaseI/II, Multicenter, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the Menin Inhibitor BN104 in the Treatment of Patients With Relapsed/Refractory Acute Leukemia
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 19, 2023
Completion date
December 31, 2027
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukaemia, all, adult, aml, adult, kmt2a rearrangement, menin inhibitors, npm1 mutation, nup98 gene rearrangement